People With Heart Failure Hospitalized Less Often When Specialists Treat Them, Study Finds

November 03, 1997

DALLAS, Nov. 4 -- People with heart failure fared far better in the care of cardiologists and trained specialists than in the hands of internists and family physicians with limited expertise in treating the condition, a new study published today in the American Heart Association journal Circulation shows.

Heart failure is a condition in which the heart can't pump enough blood to meet the demands of the body, leading to shortness of breath and fluid retention.

One reason for the improved results from specialists may be "more aggressive" therapy with diuretics -- medicines that purge the excess fluid from tissues. Those treated by specialists received higher doses of diuretics, which were shown to cut in half the rate of hospitalizations for heart problems. In addition, people treated aggressively were able to undergo exercise testing without becoming exhausted, says Sai Hanumanthu, M.D., and co-investigators at Vanderbilt University Medical Center in Nashville, Tenn.

One-year survival for the entire group of patients treated by specialists was 87 percent -- "substantially better," the researchers say, than the outcome for any other group of patients with moderate-to-severe heart failure.

"Our findings suggest that individuals with heart failure had fewer hospitalizations and fewer symptoms, such as shortness of breath, when their care was transferred from generalists to cardiologists and a support staff who specialize in the management of such patients," he says.

During the year before referral to specialists, 94 percent of the patients in the study were hospitalized; 44 percent of the patients were hospitalized during the year after referral -- a 53 percent reduction. And 88 of the individuals who were able to exercise on a treadmill at the time of referral significantly increased their exerise ability during follow-up, says Hanumanthu.

Upon referral to specialists, most of the individuals already were receiving highly effective -- but not universally prescribed -- drugs for heart failure. A surprising 76 percent were getting drugs called ACE inhibitors and 88 percent were receiving digoxin -- substantially above national averages, according to other studies. And while nearly all were getting some form of diuretic, special-care physicians considered the dosages inadequate for optimal treatment.

Within six months, average daily doses of loop diuretics were doubled, from 94 to 181 milligrams, the researchers report.

"Individuals with complicated chronic disease syndromes such as heart failure should be managed by specialists or in specialty clinics devoted to such patients," William T. Abraham, M.D., and Michael R. Bristow, M.D., of the University of Colorado say in an editorial accompanying the study. But today, they note, physicians who are not cardiologists care for 83 percent of heart failure patients.

Another factor in the improved health and reduced hospitalizations, the scientists say, was "more appropriate" use of beta-blocker drugs and "anti-arrhythmic" agents -- drugs designed to subdue irregular heartbeats. In some individuals, the occasionally controversial drugs were deemed inappropriate and were discontinued in both groups of patients.

"At present, most patients with heart failure are managed by primary-care physicians and internists with little special expertise in heart failure," Hanumanthu and his colleagues pointed out. "It is becoming clear that this system results in excessive costs and relatively poor outcomes."

Researchers looked at rates of hospitalization, drugs and peak exercise capacity at 134 patients referred to Vanderbilt's specialized heart failure and transplant program between July 1994 and June 1995. The study included 39 women and 95 men, average age 52 years.

During a time when the death rates from heart attacks and strokes declined, chronic heart failure has increased dramatically in the United States -- from 250,000 people diagnosed in 1970 to nearly 700,000 in 1992, according to Abraham and Bristow. Congestive heart failure afflicts almost 5 million Americans, or about 1.5 percent of the nation's population, they estimated.

"Specialized heart-failure centers offer complex, cost-effective treatments not available in other settings," according to Abraham and Bristow. These treatments include heart transplantation and other high-risk heart surgeries, and experimental medical treatments not yet approved by the Food and Drug Administration.

An example is carvedilol, a "third-generation" beta-blocker drug shown to be effective in treating heart failure. Before FDA approved it, carvedilol was available only in specialty heart- failure centers, the two experts say.

Monitoring of optimal drug levels was just part of intensive management program. Everyone in the study received extensive testing of the heart's main pumping chamber, the left ventricle. Heart function was monitored regularly by three physicians who work exclusively with heart failure and heart transplant patients, assisted by cardiovascular nurse specialists. All of the strategies employed are "standard practice" in specialized centers, the researchers said.

Other co-authors of the study are Javed Butler, M.D.; Don Chomsky, M.D., and Stacy Davis, M.D. John R. Wilson, M.D. directed the study.


American Heart Association

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to